Addex Therapeutics (NASDAQ:ADXN – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Monday, August 12th. Analysts expect Addex Therapeutics to post earnings of ($0.07) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.
Addex Therapeutics (NASDAQ:ADXN – Get Free Report) last released its quarterly earnings data on Thursday, June 6th. The company reported ($1.37) EPS for the quarter. The firm had revenue of $0.27 million during the quarter. Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%. On average, analysts expect Addex Therapeutics to post $-12 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Addex Therapeutics Trading Up 2.6 %
ADXN stock opened at $7.90 on Friday. Addex Therapeutics has a 1-year low of $5.00 and a 1-year high of $27.90. The firm has a market cap of $8.37 million, a PE ratio of -0.46 and a beta of 1.77. The business’s 50-day moving average price is $8.22 and its two-hundred day moving average price is $10.84.
Wall Street Analyst Weigh In
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Recommended Stories
- Five stocks we like better than Addex Therapeutics
- Insider Buying Explained: What Investors Need to Know
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MarketBeat Week in Review – 8/5 – 8/9
- Why Invest in High-Yield Dividend Stocks?
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
